Natural Oral Steroids Abiraterone Muscle Gain 154229-19-3

<

Model NO.: XXJL-154229-19-3
Trademark: XXJL
Transport Package: Discreet Packing Ways for Your Choice
Specification: GMP, ISO 9001, USP, BP, GMP, ISO 9001, USP
Origin: Wuhan
Model NO.: XXJL-154229-19-3
Trademark: XXJL
Transport Package: Discreet Packing Ways for Your Choice
Specification: GMP, ISO 9001, USP, BP, GMP, ISO 9001, USP
Origin: Wuhan

High Purity API Abiraterone for Androgen Antagonists 154229-19-3

Product Description

product Name: Abiraterone
Alias : 17-(3-Pyridyl)androsta-5,16-dien-3beta-ol
CAS: 154229-19-3
Molecular Formula: C24H31NO
Molecular Weight: 349.51
Molecular Structure:
Assay: 99%
Appearance: White powder
Grade: Pharmaceutical Grade
Storage: Shading, confined preservation
Usage: It is indicated for use in combination with prednisone as a treatment for metastatic castration-resistant prostate cancer.

Abiraterone is a drug used in combination with in metastatic castration-resistant prostate cancer (formerly hormone-resistant or hormone-refractory prostate cancer) -- i.e., prostate cancer not responding to androgen deprivation or treatment with antiandrogens.

After an expedited six-month review, abiraterone was approved by the U.S. Food and Drug Administration (FDA) in April 2011. In Phase III trials, it extended median survival to 14.8 months versus 10.9 months placebo, and the trial was stopped because of the successful outcome.

Our advantages

Quality assurance
With our years of experience, advanced technology and continuous research, our quality is to fully meet the needs of the market to meet the requirements of customers, many customers use our products, we believe that the product is very good. Whether it is a powder, or liquid, yes, we all know, our liquid better.
 
Safe transportation
Our mode of transport is taken according to each country's situation is different transportation, while our packaging, according to the latest customs situation, constantly updated, improved our packaging, we guarantee that you receive it within 3-5 to your product.
 
The product diversity
Our products are powders and liquids, yes, brothers, the effect of the liquid is very good, but many people do not use liquid, so you are very lucky, you buy our powder, we can tell you the method of making the liquid If you buy a liquid, we will tell you how to filter. We absolutely guarantee that you can very safely use our products
 
Applications

It is indicated for use in combination with as a treatment for metastatic castration-resistant prostate cancer. It has received FDA (28 April 2011), EMA (23 September 2011), MHRA (5 September 2011) and TGA (1 March 2012) approval for this indication. In Australia it is covered by the Pharmaceutical Benefits Scheme when being used to treat castration-resistant prostate cancer and given in combination with (subject to the conditions that the patient is not currently receiving chemotherapy, is either resistant or intolerant of docetaxel, has a WHO performance status of <2, and his disease has not since become progressive since treatment with PBS-subsidised abiraterone has commenced).


Other products:
 
     
     
     
33 Toremifene citrate  CAS: 89778-27-8
     
35 vardenafil  CAS: 831217-01-7
     
     
38 Dutasteride  CAS: 164656-23-9
39 Finasteride  CAS: 98319-26-7
40 Yohimbine HCl  CAS: 65-19-0

 

High Purity API Abiraterone for Androgen Antagonists 154229-19-3

Product Description

product Name: Abiraterone
Alias : 17-(3-Pyridyl)androsta-5,16-dien-3beta-ol
CAS: 154229-19-3
Molecular Formula: C24H31NO
Molecular Weight: 349.51
Molecular Structure:
Assay: 99%
Appearance: White powder
Grade: Pharmaceutical Grade
Storage: Shading, confined preservation
Usage: It is indicated for use in combination with prednisone as a treatment for metastatic castration-resistant prostate cancer.

Abiraterone is a drug used in combination with in metastatic castration-resistant prostate cancer (formerly hormone-resistant or hormone-refractory prostate cancer) -- i.e., prostate cancer not responding to androgen deprivation or treatment with antiandrogens.

After an expedited six-month review, abiraterone was approved by the U.S. Food and Drug Administration (FDA) in April 2011. In Phase III trials, it extended median survival to 14.8 months versus 10.9 months placebo, and the trial was stopped because of the successful outcome.

Our advantages

Quality assurance
With our years of experience, advanced technology and continuous research, our quality is to fully meet the needs of the market to meet the requirements of customers, many customers use our products, we believe that the product is very good. Whether it is a powder, or liquid, yes, we all know, our liquid better.
 
Safe transportation
Our mode of transport is taken according to each country's situation is different transportation, while our packaging, according to the latest customs situation, constantly updated, improved our packaging, we guarantee that you receive it within 3-5 to your product.
 
The product diversity
Our products are powders and liquids, yes, brothers, the effect of the liquid is very good, but many people do not use liquid, so you are very lucky, you buy our powder, we can tell you the method of making the liquid If you buy a liquid, we will tell you how to filter. We absolutely guarantee that you can very safely use our products
 
Applications

It is indicated for use in combination with as a treatment for metastatic castration-resistant prostate cancer. It has received FDA (28 April 2011), EMA (23 September 2011), MHRA (5 September 2011) and TGA (1 March 2012) approval for this indication. In Australia it is covered by the Pharmaceutical Benefits Scheme when being used to treat castration-resistant prostate cancer and given in combination with (subject to the conditions that the patient is not currently receiving chemotherapy, is either resistant or intolerant of docetaxel, has a WHO performance status of <2, and his disease has not since become progressive since treatment with PBS-subsidised abiraterone has commenced).


Other products:
 
     
     
     
33 Toremifene citrate  CAS: 89778-27-8
     
35 vardenafil  CAS: 831217-01-7
     
     
38 Dutasteride  CAS: 164656-23-9
39 Finasteride  CAS: 98319-26-7
40 Yohimbine HCl  CAS: 65-19-0

Â